| Lightcalls.com |
|
|
![]() |
In Eastern Bengal, in Northeast Ind...In Eastern Bengal, in Northeast India's state of Assam, and in southern India's state of Mysore, there be augmenteds an ancient medicinal botanical, the mukul myrrh tree (Commiphora mukul) a tree which conceals a resinous substance called gum guggul Classic Ayurvedic examples describe guggul's various properties, including its ability to treat obesity and lipid-metabolism. present research originally focused on the unpurified resin, the gum guggul and its ability to stir up healthy cholesterol and triglyceride of the same heights More recently, scientists have been able to purify the uncooked natural gum into a safe, non-irritating extract, referr to as gugulipid in the literature. Exploring the past to bare this botanical's use today The main actions of gugulipid are: hypolipidemic (fat lipid-lowering, important for atherosclerosis prevention), thermogenic (fat-burning, important for weight-loss), and anti-inflammatory. The active constituents of gugulipid are Z-guggulsterone and E-guggulsterone and the extract is normally standardized to a minimum of 25 percent total guggulsterones 600 BC and today. While gum guggul's weights have been used in Ayurveda for untold centuries, gugulipid has been available in India since 1988 Nevertheless the story is richer than that. In a pure Indian laboratory in 1964, C Dwarakanath discloseed a strong connection between the ancient Ayurvedic conception of medoroga of Sushruta (600 BC) and the recent understanding of the development of atherosclerosis and its oftimes fatal outcome Stage united In the ancient concept, medoroga (atherosclerosis) begins with overeating of Shleshmalahara and lack of exercise -- shleshma referring to fatty feeds Stage two is marked at "Amarasa produced at the flush of Dhatwagnipaka," incomplete digestion of nutrition at the gastrointestinal level and inadequate or disordered metabolism of nutrients and cheer components. Stage three is characterized by dint of Avrta Marga and Niruddha Marga (coating and obstruction of channels) on Medas (fats/lipids), which essentially describes build-up of lipid plaque and narrowing of vessels We can alone marvel at the incredible even of sophistication and advancement in Ayurvedic Medicine that was evident 2600 years ago. Gugulipid meditation begins. With the discovery of the hypolipidemic activity of the in a raw state gum resin, a series of investigations were carried disclosed at India's National Chemical Laboratory, Pune in conjunction with another institute in Lucknow. individual of the components of the gum (the ethylacetate soluble portion) was establish to possess hypolipidemic and anti-inflammatory activity. In hyperlipidemic animals (animals which overproduc offspring lipids), "gugulipid led to significant changes in the lipoprotein profile by the agency of reducing the serum cholesterol and triglycerides and altering the ratio of HDL [good cholesterol] to LDL [bad cholesterol]" GV Datyavati pointed disclosed in a chapter he wrote in 1991 for a multi-volume part entitled "Gugulipid: A Promising Hypolipidemic Agent from Gum Guggul" Heart disease prevention. In an early double-blind cross-over investigation by a team led on S. Prakash at India's Central Research Institute of Ayurved, which appeared in a 1976 issue of the Journal of Research in Indian Medicine (a journal produc gone out of Banaras Hindu University through India's Central Council for Research in Indian Medicine and Homeopathy), 48 enthralls who were confirmed to be at least 15 percent overweight were studied, 33 of whom received guggul for four weeks (before being given the placebo for four weeks) and 15 of whom received a placebo for four weeks (followed by dint of guggul for four weeks). The ensues showed a "statistically significant [drop] in serum total lipids, cholesterol and triglycerides" with four weeks of treatment, while no change was observ with the placebo. The investigation concluded that "gum guggul is an effective hypolipidemic agent and may suffer to be of high therapeutic value in the prevention of coronary and cerebro-vascular diseases, especially in make liables who are hyperlipidemic." Heart protection. In a studious mood of 200 patients with ischemic heart disease, RP Singh, et al. (in a contemplation which appeared in a 1993 issue of the International Journal of Pharmacognosy) achieved the following results: ECG (electrocardiogram) patterns were restored to normal; significant reductions were realized in cholesterol triglycerides, and total lipid levels; and reduc cardiac incidents (events) were observ becoming to "the cardioprotective action of guggul" pleasing convincing results. Dietary supplementation for those who are not hypolipidemic is moveed at a level which would include 25 mg of guggulsterone three times a day. COPYRIGHT 1996 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |